An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists

An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists

Abstract Background Interferon (IFN) beta drugs have been approved for the treatment of relapsing forms of multiple sclerosis (RMS) for more than 20 years and are considered to offer a favourable benefit-risk profile. In July 2014, subcutaneous (SC) peginterferon beta-1a 125 μg dosed every 2 weeks,...

Full description

Bibliographic Details
Main Authors: Annette Kolb-Mäurer, Cord Sunderkötter, Borries Kukowski, Sven G. Meuth, on behalf of the members of an expert meeting
Format: Article
Language:English
Published: BMC 2019-06-01
Series:BMC Neurology
Subjects:
Multiple sclerosis
Peginterferon bet-1a
Interferon beta
Flu-like symptoms
Injection site reactions
Management
Online Access:http://link.springer.com/article/10.1186/s12883-019-1354-y

Internet

http://link.springer.com/article/10.1186/s12883-019-1354-y

Similar Items